Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Total Current Liabilities (2022 - 2026)

HeartSciences (HSCS) has disclosed Total Current Liabilities for 4 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 52.57% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Oct 2025, down 52.57%, and an annual FY2025 reading of $3.7 million, up 111.4% over the prior year.
  • Total Current Liabilities was $1.6 million for Q4 2025 at HeartSciences, down from $3.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $3.7 million in Q2 2025 and bottomed at $1.4 million in Q3 2024.
  • Average Total Current Liabilities over 4 years is $2.5 million, with a median of $2.0 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 123.02% in 2025, while the deepest fall reached 52.57% in 2025.
  • Year by year, Total Current Liabilities stood at $3.1 million in 2022, then grew by 12.5% to $3.5 million in 2023, then decreased by 6.47% to $3.3 million in 2024, then plummeted by 52.57% to $1.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for HSCS at $1.6 million in Q4 2025, $3.0 million in Q3 2025, and $3.7 million in Q2 2025.